{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:09:51Z","timestamp":1772168991001,"version":"3.50.1"},"reference-count":16,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns3:p>Neuroleptic malignant syndrome (NMS) is a well-recognized neurologic emergency.\u00a0It presents with classic features including hyperthermia, autonomic instability, muscle hypertonia, and mental status changes.\u00a0The syndrome is potentially fatal and is associated with significant morbidity due to complications such as rhabdomyolysis, acute kidney injury, and ventricular arrhythmias due to the trans-cellular electrolyte shift.\u00a0NMS is conventionally associated with the first-generation antipsychotic agents, however, has been described with the use of atypical and novel antipsychotics including Ziprasidone.\u00a0A case of NMS with Ziprasidone use at the therapeutic dose is reported here.<\/ns3:p>","DOI":"10.12688\/f1000research.51094.1","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T10:47:22Z","timestamp":1613558842000},"page":"124","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: Ziprasidone induced neuroleptic malignant syndrome"],"prefix":"10.12688","volume":"10","author":[{"given":"Yub Raj","family":"Sedhai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6657-7871","authenticated-orcid":false,"given":"Alok","family":"Atreya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabin","family":"Phuyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soney","family":"Basnyat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Pokhrel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"870-6","DOI":"10.1176\/ajp.2007.164.6.870","article-title":"Neuroleptic malignant syndrome.","volume":"164","author":"J Strawn","year":"2007","journal-title":"Am J Psychiatry."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"185-202","DOI":"10.1016\/s0025-7125(16)30278-4","article-title":"Neuroleptic malignant syndrome.","volume":"77","author":"S Caroff","year":"1993","journal-title":"Med Clin North Am."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"301-9","DOI":"10.1002\/hup.483","article-title":"Olanzapine induced neuroleptic malignant syndrome--a case review.","volume":"18","author":"A Kogoj","year":"2003","journal-title":"Hum Psychopharmacol."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"45-62","DOI":"10.1007\/s40268-014-0078-0","article-title":"Second-Generation Antipsychotics and Neuroleptic Malignant Syndrome: Systematic Review and Case Report Analysis.","volume":"15","author":"M Murri","year":"2015","journal-title":"Drugs R D."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"748-54","DOI":"10.1016\/s0006-3223(97)00530-1","article-title":"Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: A case-control study.","volume":"44","author":"D Berardi","year":"1998","journal-title":"Biol Psychiatry."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"1217-51","DOI":"10.2165\/00003495-200262080-00015","article-title":"Ziprasidone: A review of its use in schizophrenia and schizoaffective disorder.","volume":"62","author":"N Gunasekara","year":"2002","journal-title":"Drugs."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"839-51","DOI":"10.1345\/aph.1A053","article-title":"Ziprasidone: The fifth atypical antipsychotic.","volume":"36","author":"C Caley","year":"2002","journal-title":"Ann Pharmacother."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"41-7","DOI":"10.1177\/1941875210386491","article-title":"Neuroleptic Malignant Syndrome: A Review for Neurohospitalists.","volume":"1","author":"B Berman","year":"2011","journal-title":"Neurohospitalist."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"205-7","DOI":"10.1002\/hup.578","article-title":"Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson\u2019s disease: A diagnostic challenge.","volume":"19","author":"N Gray","year":"2004","journal-title":"Hum Psychopharmacol."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"415-22","DOI":"10.1097\/01.pra.0000361282.95962.9f","article-title":"Malignant catatonia in a patient with bipolar disorder, B12 deficiency, and neuroleptic malignant syndrome: One cause or three?","volume":"15","author":"A Lewis","year":"2009","journal-title":"J Psychiatr Pract."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"42-4","DOI":"10.1080\/15622970600774202","article-title":"Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.","volume":"8","author":"M Ozen","year":"2007","journal-title":"World J Biol Psychiatry."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.4088\/jcp.v67n0420e","article-title":"Early bicarbonate loading and dantroline for ziprasidone\/haloperidol-induced neuroleptic malignant syndrome.","volume":"67","author":"J Strawn","year":"2006","journal-title":"J Clin Psychiatry."},{"key":"ref-13","first-page":"208-12","article-title":"Neuroleptic malignant syndrome: long-term follow-up of 20 cases.","volume":"52","author":"H Pope","year":"1991","journal-title":"J Clin Psychiatry."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"129-35","DOI":"10.1093\/bja\/85.1.129","article-title":"Neuroleptic malignant syndrome.","volume":"85","author":"P Adnet","year":"2000","journal-title":"Br J Anaesth."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"226-30","DOI":"10.1034\/j.1600-0447.2000.102003226.x","article-title":"Prospective evaluation of circulatory levels of catecholamines and serotonin in neuroleptic malignant syndrome.","volume":"102","author":"B Spivak","year":"2000","journal-title":"Acta Psychiatr Scand."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"2506-2516","DOI":"10.1056\/NEJMoa1808217","article-title":"Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.","volume":"379","author":"T Girard","year":"2018","journal-title":"N Engl J Med."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/10-124\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/10-124\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/10-124\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T10:35:09Z","timestamp":1615458909000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/10-124\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":16,"URL":"https:\/\/doi.org\/10.12688\/f1000research.51094.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.54209.r79895","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.54209.r79894","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.54209.r79894","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.54209.r79895","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/10-124\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.54209.r79895, Prajwal Ghimire, Department of Neurosurgery, King's College Hospital NHS Foundation Trust, London, UK, 05 Mar 2021, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/10-124\/v1#referee-response-79895","order":0,"name":"referee-response-79895","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>Alok Atreya<\/b>; \n<i>Posted: 11 Mar 2021<\/i>; Dear Dr. Ghimire, We appreciate your time you took to go through our article and write such a detailed review. We would further thank you for your positive and encouraging comments on our article.","URL":"https:\/\/f1000research.com\/articles\/10-124\/v1#referee-comment-6438","order":1,"name":"referee-comment-6438","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.54209.r79894, Ashish Saraf, Department of Forensic Medicine and Toxicology, All India Institute of Medical Sciences, Gorakhpur, Uttar Pradesh, India, 09 Mar 2021, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/10-124\/v1#referee-response-79894","order":2,"name":"referee-response-79894","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>Alok Atreya<\/b>; \n<i>Posted: 11 Mar 2021<\/i>; Dear Dr. Saraf, We thank you for your time to go through our article. We further thank your for highlighting the important findings and positive comments. We are really encouraged.","URL":"https:\/\/f1000research.com\/articles\/10-124\/v1#referee-comment-6439","order":3,"name":"referee-comment-6439","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":4,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}